Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 840 (1 August 2008) | doi:10.1038/nbt0808-840
GSK slashes internal R&D
Abstract
Job cuts at its Centres of Excellence for Drug Discovery (CEDD) in the US, UK and Italy, accompanied by an expansion of research in China, are raising questions about where GlaxoSmithKline (GSK) is going next in its bid to boost R&D productivity. Although it acknowledges 350 of 16,000 R&D jobs have been cut, the London-based company has recently announced it remains committed to the CEDD model and considers it to have been successful.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
